Respiratory viruses
Leyden Labs Secures $70 Million Funding to Develop Broad Protection Against Respiratory Viruses
Leyden Labs, Respiratory viruses, Influenza, Nasal defenses, Broad protection, PanFlu, Mucosal Protection Platform, Biotech funding
Vicebio Secures $100 Million Funding to Advance Multivalent Respiratory Virus Vaccines
Vicebio, Multivalent Respiratory Virus Vaccines, $100 Million Funding, Series B Funding Round, Molecular Clamp Technology, RSV and hMPV Vaccine Combo
Moderna’s Combination Flu and COVID-19 Vaccine Shows Promising Results in Late-Stage Trial
Moderna, flu vaccine, COVID-19 vaccine, combination vaccine, mRNA-1083, late-stage trial, immune response, influenza, SARS-CoV-2, respiratory viruses